Recursion Pharmaceuticals, Inc. (RXRX)

Recursion Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	74.68	58.84	44.58	39.84	10.18
Revenue Growth (YoY)	26.92%	32.00%	11.88%	291.46%	156.89%
Cost of Revenue	546.22	359.66	283.81	203.97	135.27
Gross Profit	-471.54	-300.82	-239.24	-164.13	-125.09
Selling, General & Admin	176.59	178.18	110.82	81.6	57.68
Operating Expenses	176.59	178.18	110.82	81.6	57.68
Operating Income	-648.13	-479	-350.06	-245.73	-182.78
Interest Expense	-1.81	-1.57	-0.1	-0.06	-2.95
Interest & Investment Income	22.79	15.76	19.12	6.25	0.07
Other Non Operating Income (Expenses)	-17.74	0.03	-1.09	0.05	0
EBT Excluding Unusual Items	-644.9	-464.79	-332.13	-239.48	-185.65
Other Unusual Items	-	-	-	-	-0.83
Pretax Income	-644.9	-464.79	-332.13	-239.48	-186.48
Income Tax Expense	-0.14	-1.13	-4.06	-	-
Net Income	-644.76	-463.66	-328.07	-239.48	-186.48
Net Income to Common	-644.76	-463.66	-328.07	-239.48	-186.48
Shares Outstanding (Basic)	447	274	208	176	125
Shares Outstanding (Diluted)	447	274	208	176	125
Shares Change (YoY)	63.18%	31.92%	18.41%	40.04%	475.48%
EPS (Basic)	-1.44	-1.69	-1.58	-1.36	-1.49
EPS (Diluted)	-1.44	-1.69	-1.58	-1.36	-1.49
Free Cash Flow	-378.28	-372.87	-299.74	-120.58	-198.41
Free Cash Flow Per Share	-0.84	-1.36	-1.44	-0.69	-1.58
Operating Margin	-867.87%	-814.09%	-785.33%	-616.74%	-1795.79%
Profit Margin	-863.35%	-788.02%	-735.99%	-601.05%	-1832.18%
Free Cash Flow Margin	-506.52%	-633.71%	-672.43%	-302.64%	-1949.42%
EBITDA	-564.43	-442.51	-325.66	-233.97	-174.37
D&A For EBITDA	83.7	36.49	24.4	11.76	8.41
EBIT	-648.13	-479	-350.06	-245.73	-182.78
Revenue as Reported	74.68	58.84	44.58	39.84	10.18

Updated Feb 25, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q